The role of carboplatin in combination with paclitaxel in patients with castration-resistant prostate cancer.
Nikol RusarovaDenisa VitaskovaHana KalabovaAndrea OndruskovaDana PurovaBohuslav MelicharHana ŠtudentováPublished in: Future oncology (London, England) (2022)
Background: The aim of the present study was to examine the efficacy of carboplatin in combination with paclitaxel in patients with metastatic castration-resistant prostate cancer pretreated with multiple regimens including docetaxel and androgen receptor-targeted agents. Methods: Clinical data from patients treated with carboplatin plus paclitaxel were collected retrospectively from a single institution. Results: 43 patients with metastatic castration-resistant prostate cancer were identified. Median number of cycles was ten (range: 1 to 23), prostate-specific antigen response was observed in 18 (42%) patients, median progression-free survival was 115 days and median overall survival was 8.1 months. Conclusion: Combination chemotherapy using taxane with carboplatin is an effective and well-tolerated therapy in heavily pretreated patients with metastatic castration-resistant prostate cancer.
Keyphrases
- free survival
- phase ii study
- locally advanced
- end stage renal disease
- phase iii
- ejection fraction
- chemotherapy induced
- prognostic factors
- peritoneal dialysis
- randomized controlled trial
- clinical trial
- rectal cancer
- stem cells
- big data
- radiation therapy
- drug delivery
- mesenchymal stem cells
- patient reported
- data analysis
- smoking cessation